Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rutherford

Showing results (481-490 of 603) with videos related to

Pageof 61
Sort By:
American Journal of Obstetrics and Gynecology|April 16, 2013
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupiloneDana M Roque, Stefania Bellone, Natalia Buza, et al.
Journal of Cancer Research and Clinical Oncology|June 15, 2007
IGF-II promoter methylation and ovarian cancer prognosisA C Beeghly, D Katsaros, A L Wiley, et al.
Cancer|January 2, 2009
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancerStefania Bellone, Simone Anfossi, Timothy J O'Brien, et al.
Gynecologic Oncology|December 3, 2014
A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancerVictoria Plamadeala, Joseph L Kelley, John K Chan, et al.
Gynecologic Oncology|August 16, 2014
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivoCarlton L Schwab, Diana P English, Dana M Roque, et al.
Cancer Epidemiology|November 23, 2024
Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivorsEline de Heus, Saskia F A Duijts, Jan Maarten van der Zwan, et al.
The American Journal of Cardiology|November 1, 1983
Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patientsR E Rude, W K Poole, J E Muller, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 2, 2024
Spatially restricted ecto-5'-nucleotidase expression promotes the growth of uterine leiomyomas by modulating Akt activityXiaofang Guo, Maja Okuka, Brittney Short, et al.
American Journal of Obstetrics and Gynecology|November 4, 2008
Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancerStefania Bellone, Simone Anfossi, Timothy J O'Brien, et al.
American Journal of Obstetrics and Gynecology|September 6, 2011
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibodyJoyce Varughese, Emiliano Cocco, Stefania Bellone, et al.
Pageof 61

Showing results (481-490 of 603) with videos related to

Sort By:
Pageof 61
American Journal of Obstetrics and Gynecology|April 16, 2013
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupiloneDana M Roque, Stefania Bellone, Natalia Buza, et al.
Journal of Cancer Research and Clinical Oncology|June 15, 2007
IGF-II promoter methylation and ovarian cancer prognosisA C Beeghly, D Katsaros, A L Wiley, et al.
Cancer|January 2, 2009
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancerStefania Bellone, Simone Anfossi, Timothy J O'Brien, et al.
Gynecologic Oncology|December 3, 2014
A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancerVictoria Plamadeala, Joseph L Kelley, John K Chan, et al.
Gynecologic Oncology|August 16, 2014
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivoCarlton L Schwab, Diana P English, Dana M Roque, et al.
Cancer Epidemiology|November 23, 2024
Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivorsEline de Heus, Saskia F A Duijts, Jan Maarten van der Zwan, et al.
The American Journal of Cardiology|November 1, 1983
Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patientsR E Rude, W K Poole, J E Muller, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 2, 2024
Spatially restricted ecto-5'-nucleotidase expression promotes the growth of uterine leiomyomas by modulating Akt activityXiaofang Guo, Maja Okuka, Brittney Short, et al.
American Journal of Obstetrics and Gynecology|November 4, 2008
Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancerStefania Bellone, Simone Anfossi, Timothy J O'Brien, et al.
American Journal of Obstetrics and Gynecology|September 6, 2011
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibodyJoyce Varughese, Emiliano Cocco, Stefania Bellone, et al.
Pageof 61